The impact of the classical, lectin and alternative pathways of complement activation on protective immunity against Streptococcus pneumoniae infection following vaccination with established pneumococcal vaccines.

Hypothesis and the aims of my study:
This is the aims of my study (This project aims to define the contribution of the individual activation pathways of complement towards vaccine-induced immunity against S.pneumoniae. Using gene-targeted mouse strains (C1q deficient mice, MASP-2 deficient mice and Factor B deficient mice).
I need more details about the hypothesis and breakdown my project aims (275 – 400 words).

Introduction:

C1q Protein in mice:
I wrote about The Classical Pathway of Complement Activation, but I need more specific information about C1q protein with its structure and put figure about it. (200 words).

C1q Deficiency in mice (C1q-/-):
I wrote about Deficiencies of the classical pathway, but I need more specific information about C1q Deficiency in mice. (350 words).

MASP-2 Protein in mice:
I wrote about Lectin Pathway of Complement Activation, but I need more specific information about MASP-2 Protein with its structure and put figure about it. (200 words).

MASP-2 Deficiency in mice (MASP-2-/-):
I wrote about Deficiencies of the Lectin pathway, but I need more specific information about MASP-2 Deficiency in mice. (350 words).

Factor B Protein in mice (fB):
I wrote about The alternative Pathway of Complement Activation, but I need more specific information about factor B protein with its structure and put figure about it. (200 words).

Factor B Deficiency in mice (fB-/-):
I wrote about Deficiencies of the alternative pathway, but I need more specific information about factor B Deficiency in mice. (350 words).

Antibody structure in mice:
General information (550 words).

Then more details about IgG antibody in mice (225 words).

Anti-pneumococcal antibody in mice:
General information (500 words).

Anti-pneumococcal polysaccharide vaccines antibody:
General information (200-300 words).
Then add more details about the vaccines components (Anti-CRM197 protein antibody in mice, Anti-pneumococcal polysaccharide vaccine (PneumovaxII) antibody and Anti-prevenar 13 vaccine antibody in mice). My study focusing on IgG level (see my results). Mice immunised with 20 μg of CRM197 protein single or multiple immunisation. Another group of mice immunised with 1 μg of PneumovaxII vaccine single or multiple immunisation. Final group of mice immunised with Prevenar13 (which is contain 13 types of Pneumococcal polysaccharide and CRM197 protein) the mice dose is (human dose /25 which equal same velum 1 μg of PneumovaxII vaccine) single or multiple immunisation. (525-625 words)

Antibody titre in mice:
General information (150-200 words).
Measurement of IgG antibody level using ELISA technique (600-650 words).

B and T cells responses in mice (This title you can divide it to 2 titles):
General information (675 words).
Focusing on CD’s antibody markers (( CD3, CD4, CD8, CD25, CD19 and CD45R/B220 )) which I used in my study to measure B and T cells responses in spleen cells in mice immunised with CRM197 or PneumovaxII or Prevenar13 ( check my results).

about ((( 5500 words ))) 20 pages

(( NOTIES: Please, don’t rebate the information between the figures or between the tables )))

((( this is my results organiser. if you think about different organiser better than this please let me know and do it )))

All tables are using to explain the Statistical analysis between point to point in the GRAPH above it each table; which I used Student t test was performed using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA.

Results:

Chapter 1:
C3 depositions:
• C3 deposition on CRM197 protein:
• C3 deposition on Pneumococcal Polysaccharides Vaccine (PneumovaxII):
• C3 deposition on Pneumococcal Polysaccharides Conjugated Vaccine (Prevnar13):
• C3 deposition on S. Pneumoniae D39:
• C3 deposition in WT mice on S. pneumoniae D39 under (LP) and (AP)

Discussion: (for chapter 1)

Chapter 2:
Antibody titre for mice immunised with CRM197 Protein:
• mice immunised in day1 and day 45:
• mice immunised in day1, 8, 15 and day 22:
• mice immunised in day1, 8, 15 and day 45:

Discussion: (for chapter 2)

Chapter 3:
Antibody titre for mice immunised with Pneumococcal Polysaccharide Vaccine (PneumovaxII):

• impact of Doses and Routes of PneumonaxII
• mice immunised in day1 and day 45:

• mice immunised in day1, 8, 15 and day 45:

Discussion: (for chapter 3)

Chapter 4:
– Antibody titre for mice immunised with Pneumococcal polysaccharide conjugate vaccine (Prevnar13):

• impact of Doses of Prevnar13:

• mice immunised in day1 and day 45:
– Antibody titer for whole Prevnar 13 vaccine
– Antibody titer for Pneumococcal Polysaccharide components
– Antibody titer for CRM197 Protein component
• Discussion: (for chapter 4 [mice immunised in day1 and day 45])

• mice immunised in day1, 8, 15 and day 45:

– Antibody titer for whole Prevnar 13 vaccine
– Antibody titer for Pneumococcal Polysaccharide components
– Antibody titer for CRM197 Protein component
• Discussion: (for chapter 4 [mice immunised in day1, 8, 15 and day 45])

Discussion: (for chapter 4 all 3 titles together).

Final (summary) Discussion: [ALL CHAPTERS 2,3 AND 4 TOGETHER] ( about 2000 words )

NOTIES for Discussions: You can use (the Appendix C: Clinical signs during the experiments), in discussion ( BUT, if you used it in Discussion part you have to remove it from APPENDIX).

APPENDIX chapter: (No more than 550 words) [Which is count it from Results and discussions words]

Results and discussions about ((( 15125 words ))) 55 pages

+

Summary of the Discussion: (all the results together [Chapter 1, 2, 3 and 4]) I need Final summery for all results and discussion together (750 words)

+

I need Abstract (350 words)